MedPath
NMPA Approval

Budesonide and Formoterol Fumarate Inhalation Aerosol (III)

国药准字HJ20240069

June 28, 2024

Drug Information

布地奈德福莫特罗吸入气雾剂(Ⅲ)

吸入气雾剂

每瓶120揿,每揿含布地奈德185 μg和富马酸福莫特罗(以(C₁₉H₂₄N₂O₄)₂·C₄H₄O₄计)5.5 μg,递送剂量为布地奈德160 μg和富马酸福莫特罗(以(C₁₉H₂₄N₂O₄)₂·C₄H₄O₄计)4.8 μg

化学药品

June 28, 2024

June 27, 2029

Company Information

Applicant Company

1800 Concord Pike, Wilmington, DE 19803 United States of America

Manufacturing Company

224 Avenue de la Dordogne, Dunkerque 59640, FRANCE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

布地奈德福莫特罗吸入气雾剂(Ⅲ) - NMPA 批准文号 | MedPath